Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Global Pharma With Investment Subsidiary Seeks Companies Developing Novel Drugs, Open to Various Modalities

16 Dec

The firm is a publicly listed pharmaceutical company with a global workforce and an international footprint that includes over 40 branches and subsidiaries worldwide. The firm’s core businesses are active pharmaceutical ingredients and generic drugs, while the firm is rapidly expanding into innovative drug development, including small molecules, biologics, and cell and gene therapies. A U.S.-based subsidiary operates as an integrated platform with research and development, manufacturing, and commercial capabilities, supplying generic drugs to major pharmacy chains, mass retailers, and grocery channels. 

Another subsidiary of the firm is responsible for equity investments and business development activities, including in-licensing and supplier or distributor partnerships, across both the China and U.S. markets. 

The firm is most interested in companies developing novel drugs across biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. From a development-stage perspective, the firm prefers programs at or before the NDA stage, including preclinical, Phase I, Phase II, Phase III, and NDA-ready assets. 

In addition to general equity investment and business development opportunities, the firm has particular interest in late-stage clinical assets that can be in-licensed and introduced into the China market, technologies that improve API manufacturing and production efficiency, and injectable drug products. The firm is also interested in distribution rights in China for both innovative and generic drugs, as well as distribution rights in the United States, primarily for generic drugs. 

From a company and management team perspective, the firm generally favors partners with strong scientific and technical capabilities, clear development and regulatory strategies, and high-quality data packages that support clinical and commercial potential. The firm typically values management teams that demonstrate execution capability, openness to strategic collaboration, and a willingness to engage in cross-border partnerships aligned with manufacturing, regulatory, and commercialization objectives. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: Europe-Based VC Firm With Strong Track Record Invests Up to €20M, Open to All Life Science & Healthcare Sectors 

16 Dec

The firm is a leading European venture capital firm investing in early- and growth-stage life science companies. The firm focuses on biotechnology, therapeutics, medical technology, diagnostics, digital health, and life science tools. The firm has a long track record of supporting innovative companies as they translate scientific breakthroughs into high-growth businesses. To date, the firm has invested in more than 60 life science companies, including multiple successful acquisitions by large pharmaceutical and medical technology companies. Initial investment sizes typically range from EUR 5–10 million, with the potential to invest up to EUR 20 million over the life of an investment. 

The firm invests primarily in Europe and selectively in the United States across five broad areas: therapeutics, medtech, diagnostics, digital health, and biotechnology and R&D tools. Within therapeutics, the firm focuses on early-stage companies with preclinical proof-of-concept data or programs approaching clinical entry, with a preference for highly innovative technology platforms and opportunities supported by early clinical data. In other sectors, the firm prefers companies with product candidates supported by strong intellectual property that are approaching regulatory approval or companies that have already launched a first product and achieved early market traction. 

From a company and management team perspective, the firm typically seeks a board seat and places strong emphasis on experienced, high-quality management teams. At the same time, the firm actively supports highly talented entrepreneurs and works closely with portfolio companies to help drive strategic, operational, and commercial execution. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Invests up to $3M Across 4 Pillars of Medical Devices

2 Dec

A venture capital firm with offices in the U.S. and Europe, with a dual-fund structure, invests across several industries, with one of its focuses in healthtech and medtech. The firm’s sweet spot on early-stage companies, focused on Pre-seed to Series A, with potential follow-on investment in Series B. Typical check sizes range from $ 500K – $ 3M. Geographically, the firm is open to opportunities globally and does not have a preference for leading or co-investing in rounds. 

Within life science and healthcare, the firm is interested in Medical Devices through a 4-Pillar focus: (1) Early detection technologies, (2) Robotics, automation, precision medicine, and minimally invasive devices, (3) Digital health and applications, (4)  Brain–computer interface 

Traditional biotech therapeutics is generally not of interest. The firm is agnostic in terms of indications/disease areas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: French VC Firm Seeks Companies Intersecting Deep-Tech and Life Sciences 

2 Dec

A French venture capital firm historically focused on deep-tech and hardware but is now broadening their scope to sectors such as the intersection between deep-tech and life sciences. Currently investing from their second fund of USD $75M, the firm participates in Pre-Seed and Seed rounds, typically allocating between USD $500K – $2.5M. The firm prefers to lead or co-lead and looks at companies in Europe and the U.S. 

In terms of life sciences, the firm is open to digital health deep-tech companies but are not interested in apps. The firm does not look at traditional therapeutics but will look at therapeutics with a data component or multi-asset and platform technologies. The firm is also open to diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm looks at companies that are in their pre-clinical and development stages. The firm is disease-agnostic. 

The firm may take a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Longevity-Focused VC Firm Invests $500K – $1.5M in the U.S. and Europe 

2 Dec

A venture capital firm founded in 2024 and has USD $40M under management seeks to invest in Pre-Seed and Seed stage longevity biotech companies developing technologies that can significantly extend healthy human lifespan and are scalable for everyone. Initial check size ranges between USD $250K – $1.5M with the ability to lead or co-lead. The firm is open to global companies but prefers the US, UK, and EU. 

The firm is open to all technologies, except single assets, that address longevity. Areas of interest include breakthroughs in multiple areas including AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, tissue engineering, and more. Every company they invest in must have the potential to extend healthy human lifespan by at least 10+ years. Companies of interest are typically still in pre-clinical stages. The firm seeks out companies with a strong ethical foundation and robust scientific backing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: US-Based Venture Studio and Accelerator Funds Up to $5M to Very Early-Stage Traditional Therapeutic Modalities  

2 Dec

A venture studio and accelerator that was created as a joint venture between a traditional VC firm and CRO identifies promising early-stage technologies with academic institutional foundations that are not yet ready for institutional investment. The group provides hands-on operational expertise and up to $5M of funding per company to help translate these innovations into viable startups. 
 
In their model, the institutional principal investigators are positioned as company founders, while the group’s CEO and CSO serve as interim executives to help guide early development in conjunction with the broader team. Once the company demonstrates sufficient progress, the VC firm that backs the group would plan to lead a Series A financing. 
 
The group is evolving its traditional venture studio approach to work with early-stage companies that have already been incorporated, and which would benefit from the same operational and strategic support and funding to accelerate achievement of proof of concept and enable access to VC funding or pharma partnerships. The group is currently focused on technologies and companies that are based in the U.S. 

The group focuses exclusively on traditional therapeutics. Although modality-agnostic, the group prefers traditional modalities such as small molecules and biologics. In terms of indication areas, there is particular interest in oncology, kidney disease, fibrosis, immunology and inflammation, and cardiovascular disease. However, the group remains open to other opportunities that address compelling unmet needs and present a sizeable market opportunity. The group targets early programs and considers in-clinic assets to be too late-stage for its investment model. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Late-Stage Venture & Growth Equity Investor Backing De-Risked Therapeutics and Medical Device Opportunities

18 Nov

A venture capital and private equity firm focuses on investments in the life sciences sector, with a primary emphasis on pharmaceuticals and therapeutics, and a secondary interest in medical devices. The firm invests from Series A through growth-stage transactions and is currently deploying capital from its third fund. Typical investment sizes range from $10 million to $40 million. 

The firm prioritizes opportunities with a de-risked clinical development pathway, such as those involving repurposed or reformulated drugs, established mechanisms of action, 505(b)(2) regulatory strategies, or programs with proof-of-concept clinical data. For therapeutic assets, the firm primarily targets clinical-stage companies, ideally with completed Phase I trials. For medical devices, the firm considers clinical-stage opportunities with a clear regulatory and commercialization path. The firm is indication-agnostic but maintains a strong interest in 505(b)(2) products.  
 
The firm seeks companies with a clearly defined path to regulatory approval, supported by robust intellectual property and market exclusivity. It plays an active role in its portfolio companies and takes a board seat in every investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →